Risk factors for Alzheimer's diseases: An overview for clinical practitioners

Consultant Pharmacist

Volumn 20, Issue 3, 2005, Pages 224-230

  Kim, Kye Y ^a,b   Wood, Brian E ^a   Wilson, Monica I ^a,c,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c University of Shenandoah   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Clinicians; Risk factors

Indexed keywords

ALUMINUM; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTACID AGENT; ANTIHISTAMINIC AGENT; APOLIPOPROTEIN E4; CHOLESTEROL; CLIOQUINOL; COPPER; HOMOCYSTEINE; HORMONE; INSULIN; IRON; MYELIN; NEUROLEPTIC AGENT; PRESENILIN 1; PRESENILIN 2; THYROTROPIN; VITAMIN; ZINC;

AGE; ALZHEIMER DISEASE; CARDIOVASCULAR DISEASE; DELIRIUM; DEPRESSION; DISEASE ASSOCIATION; DOWN SYNDROME; EDUCATION; FAMILY HISTORY; GENDER; GENE MUTATION; GENOTYPE; HEAD INJURY; HEALTH CARE COST; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE; NONHUMAN; OBESITY; PATIENT EDUCATION; PERSONALITY; PREVALENCE; REVIEW; RISK FACTOR;

EID: 15244341539     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2005.224     Document Type: Review

References (78)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition. Text revision. Washington, DC: American Psychiatric Association; 2000.
2. Statistics. Alzheimer's Association home page. Available at www.alz.org.
3. Physician and health care professionals: general statistics/demographics. Alzheimer's Association home page. Available at www.alz.org.
4. Alzheimer's and related dementia fact sheet. Patients and caregivers. American Associations for Geriatric Psychiatry home page. Available at www.aagponline.org.
5. Blazer DG, Hays JC. Learning the language of clinical research. In: An introduction to clinical research in psychiatry. New York, NY: Oxford University Press; 1998:39-53.
6. Blacker D. New insights into genetic aspects of Alzheimer's disease: does genetic information make a difference in clinical practice? Postgrad Med 2000;108:119-29.
7. Schellenberg GD, Bird TD, Wijsman EM et al. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 1992;258:668-71.
8. Levy-Lahad E, Wasco W. Poorkaj P et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995;269:973-7.
9. Mohs RC, Breitner JC, Silverman JM et al. Alzheimer's disease: morbid risk among first degree relatives approximates 50% by 90 years of age. Arch Gen Psychiatry 1987;44:405-8.
10. van Duijn CM, Stijnen T, Hofman A. Risk factors for Alzheimer's disease: overview of the EURODEM collaborative re-analysis of case-control studies. Int J Epidemiol 1991;20 (suppl 2):s1-s73.
11. Wisniewski KE, Wisniewski HM, Wen GY. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Downs syndrome. Ann Neurol 1985;7:278-82.
12. Geldmacher DS. Introduction: history, epidemiology and public health issues. In: Contemporary diagnosis and management of Alzheimer's dementia. Newtown, PA: Handbooks in Health Care Co; 2003.
13. Lott ID, Head E. Down syndrome and Alzheimer's disease: a link between development and aging. Ment Retard Disabil Res Rev 2001;7:172-8.
14. Schupf N, Kapell D, Nightingale B et al. Specificity of the five-fold increase in AD in mothers of adults with Downs syndrome. Neurology 2001;57:979-84.
15. McLean CA, Beyreuther K, Masters CL. Molecular pathology of early-onset dementia. In: Hodges JR, ed. Early-onset dementia. New York, NY: Oxford University Press; 2001.
16. Corder E, Saunders A, Strittmatter W et al. Genetic dose of apolipoprotein E type 4- allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-3.
17. Meyers RH, Schaefer EJ, Wilson, PW et al. Apolipoprotein E e4 association with dementia in a population-based study: the Framingham Study. Neurology 1996;46:673-7.
18. Green RC, Relkin N, Whitehouse PJ et al. Among adult offspring of persons with Alzheimer's disease, who will elect to pursue risk assessment Apo E disclosure. Preliminary results from the REVEAL study. Neurology 2002;58:A40.
19. Roberts S, Relkin N, Whitehouse PJ et al. Reasons for pursuing genetic susceptibility testing for Alzheimer disease: preliminary findings from the REVEAL Study. Neurology 2002;58:A41
20. Evans DA, Funkenstein HM, Albert MS et al. Prevalence of Alzheimer's disease in a community population of older persons, higher than previously reported. JAMA 1989;262:2551-6.
21. Scoog I, Nilson L, Palmertz B et al. A population-based study of dementia in 85 year olds. N Engl J Med 1993;328:153-8.
22. Ebly EM, Parhad IM, Hogan DB et al. Prevalence and type of dementia in the very old: results from the Canadian Study of Health and Aging. Neurology 1994;44:1593-600.
23. Heeren TJ, Laggay AM, Hijmans W et al. Prevalence of dementia in the oldest old of a Dutch community. J Am Geriatr Soc 1991;39:755-9.
24. Fratiglioni L, Grut M, Forsell Y et al. Prevalence of Alzheimer's disease and other dementia in an elderly urban population: relationship with age, sex, and education. Neurology 1991;41:1886-92.
25. Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: the quantitative integration of the literature. Acta Psychiatr Scand 1987;76:465-79.
26. Paykel ES, Brayne C, Huppert FA et al. Incidence of dementia in a population older than 75 years in the United Kingdom. Arch Gen Psychiatry 1994; 51:325-32.
27. Qiu C, Backman L, Winblad B et al. The influence of education on clinically diagnosed dementia incidence and mortality data from the Kungsholmen Project. Arch Neurol 2001;58:2034-9.
28. Ott A, van Rossum CT, Hanskamp F et al. Education and the incidence of dementia in a large population-based study: the Rotterdam Study. Neurology 1999;52:663-6.
29. Launer LT, Andersen K, Dewey ME et al. Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia. Neurology 1999;52:78-84.
30. Lindsay J, Laurin D, Verreault R et al. Risk factors for Alzheimer's disease: prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 2002;156:445-3.
31. Ott A, Bretcler M, van Hanskamp F et al. Prevalence of Alzheimer's and vascular dementia: association with education. The Rotterdam Study. BMJ 1995;310:970-3.
32. Heyman A. Estimated prevalence of dementia among elderly black and white community residents. Arch Neurol 1991;48:594-8.
33. Munoz DG, Ganapathy GR, Eliasziw M et al. Educational attainment and socioeconomic status of patients with autopsy-confirmed Alzheimer disease. Arch Neurol 2000;57:85-9.
34. Satz P. Brain reserve capacity on symptom outset after brain injury: a formulation and review of evidence for threshold theory. Neuropsychology 1993;7:273-95.
35. Plassman BL, Havlik RJ, Steffens DC et al. Documented head injury in early adulthood and risk of Alzheimer's disease and other dementia. Neurology 2000;55:1158-66.
36. Fleminger S, Oliver DL, Lovestone S et al. Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication. J Neurol Neurosurg Psychiatry 2003;74:857-62.
37. Mayeux R, Ottman R, Maestre G et al. Synergistic effects of traumatic head injury and apolipoprotein epsilon 4 in patients with Alzheimer's disease. Neurology 1996;5:555-7.
38. Millar K, Nicoll JA, Thornhill S et al. Long-term neuropsychological outcome after head injury: relation to APOE genotype. J Neurol Neurosurg Psychiatry 2003;74:1047-52.
39. Kalaria RN, Skoog I. Overlap with Alzheimer's disease. In: Erkinjuntti T, Gauthier S, eds. Vascular cognitive impairment. Philadelphia, PA: Dunitz; 2002.
40. Snowdon DA, Greiner LH, Mortimer JA et al. Brain infarction and the clinical expression of Alzheimer's disease: The Nun Study. JAMA 1997;277: 813-7.
41. Honig LS, Tang M-X, Albert S et al. Stroke and the risk of Alzheimer's disease. Arch Neurol 2003;60:1707-12.
42. Skoog I. The relationship between blood pressure and dementia: a review. Biomed Pharmacother 1997;51:367-5.
43. Kivipelto M, Helkala EL, Laakso MP et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001;322:1447-51.
44. Samuels SC, Davis KL. Advances in the treatment of Alzheimer's disease. In: Weiner MF, Lipton AM, eds. The dementia. Washington, DC: American Psychiatric Publishing, Inc.; 2003.
45. Doll, R. Review: Alzheimer's disease and environmental aluminum. Age Ageing 1993;22:138-53.
46. Martyn CN, Baker DJP, Osmond C et al. Geographical relation between Alzheimer's disease and aluminum in drinkinp water. Lancet 1989;1:59.
47. The Canadian Study of Health and Aging: risk factors for Alzheimer's disease in Canada. Neurology 1994;44:2073-80.
48. Rogers MA, Simon DG. A preliminary study of dietary aluminum intake and risk of Alzheimer's disease. Age Ageing 1999;28:205-9.
49. Lovell MA, Robertson JD, Teesdale WJ et al. Copper, iron, and zinc in Alzheimer's disease senile plaques. J Neuro Sci 1998;151:47-52.
50. Cherney RA, Atwood CS, Xilinas ME et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001;30:665-76.
51. Kukull WA, Larson EB, Bowen JD et al. Solvent exposure as a risk factor for Alzheimer's disease: a case-control study. Am J Epidemiol 1995;141:1059-71.
52. Erkinjuntii T, Wikstrom J, Palo J et al. Dementia among medical inpatients. Arch Intern Med 1986;146:1923-6.
53. Inouye SK, Charpentier PA. Precipitating factors for delirium in hospitalized elderly persons: predictive model and interrelationship with baseline vulnerability. JAMA 1996;275:852-7.
54. Rockwood K, Cosway S, Carver D et al. The risk of dementia and death after delirium. Age Ageing 1999;28:551-6.
55. Speck CE, Kukull WA, Brenner DE et al. History of depression as a risk factor for Alzheimer's disease. Epidemiology 1995;6:366-9.
56. Jorm AF. Is depression a risk factor for dementia or cognitive decline? A review. Gerontology 2000;46:219-27.
57. Wilson RS, Barnes LL, Mendes L. Depression symptoms, cognitive decline, and risk of AD in older persons. Neurology 2002;59:364-70.
58. Lindsay J, Laurin D, Verreault R et al. Risk factors for Alzheimer's disease: a perspective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 2002;156:445-3.
59. Gree RC, Cupples LA, Kurz A et al. Depression as a risk factor for Alzheimer's disease: the MIRAGE Study. Arch Neurol 2003;60:753-9.
60. Copeland MP, Daly E, Hines V et al. Psychiatric symptoms and prodromal Alzheimer's disease. Alzheimer Dis Assoc Disord 2003;17:1-8.
61. Brodaty KM, Sachdev P, Koschera A et al. Long-term outcome of late-onset schizophrenia: 5-year follow-up study. BJP 2003;183:213-9.
62. Flegal KM, Carroll MD, Kuczmarski RJ et al. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 1998;22:39-47.
63. Gustafson D, Rothenberg E, Blennow K et al. An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med 2003;163:1524-8.
64. Leibson CL, Rocca WA, Hanson VA et al. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 1997;145:301-8.
65. Ott A, Stolk RP, Hofman A et al. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 1996;39:1392-7.
66. Arvanitakis Z, Wilson RS, Bienias JL et al. Diabetes mellitus and risk of Alzheimer's disease and decline in cognitive function. Arch Neurol 2004;61:661-6.
67. Watson GS, Peskind ER, Asthana S et al. Insulin increases CSF beta amyloid 42 levels in normal older adults. Neurology 2003;60:1899-903.
68. Oken RJ. Antihistamines, a possible risk factor for Alzheimer's disease. Med Hypotheses 1995;44:47-8.
69. Itzhaki RF, Lin W-R, Shang D et al. Herpes simplex virus type 1 in brain and risk of Alzheimer's disease. Lancet 1997;349:241-4.
70. Selhub J, Jacques PF, Bostom AG et al. Association between plasma homocysteine concentrations and extracranial carotid artery stenosis. N Engl J Med 1995;332:286-91.
71. Diaz-Arrastia R. Hyperhomocysteinemia: a new risk factor for Alzheimer's disease? Arch Neurol 1998;55:1407-8.
72. Seshadri S, Beiser A, Selhub J et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002;346:476-83.
73. Ganguli M, Burmeister LA, Seaberg EC et al. Association between dementia and elevated TSH: a community-based study. Biol Psychiatry 1996;40:714-25.
74. LeBlanc ES, Janowsky J, Chan BK et al. Hormonal replacement therapy and cognition: systematic review and meta-analysis. JAMA 2001;285: 1489-99.
75. Buckwalter JG, Crooks VC, Robins SB et al. Hormone use and cognitive performance in women of advanced age. JAGS 2004;52:182-6.
76. Espeland MA, Rapp SR, Shumaker SA et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291:2959-68.
77. Shumaker SA, Legault C, Kuller L et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in post-menopausal women: Women's Health Initiative Memory Study. JAMA 2004;291:2947-58.
78. Mayeux R, Saunders AM, Shea S et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's disease. N Engl J Med 1998;338:506-11.